Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

While Hims offers more options for sexual health ... Read on for our full review and how to decide which one may work best for you. Our Medical Standards and Insights team has carefully researched ...

Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $27.00 price ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers turned in tremendous revenue and profitability growth in the fourth quarter. The company also issued very robust guidance. However, it will stop selling semaglutide-based weight-loss ...

Our product reviews offer independent views with hands-on opinion and honest verdicts aimed to give you all the important information you need to make the best buying decisions.